Core Viewpoint - The stock of He Yu-B (02256) has risen over 6%, reaching a new high of 18 HKD, driven by recent share buybacks and positive financial performance [1] Group 1: Stock Performance - He Yu-B's stock price increased by 5.56% to 17.84 HKD, with a trading volume of 34.38 million HKD [1] - The company has conducted share buybacks, repurchasing 200,000 shares on August 27 and another 100,000 shares on August 28, totaling 9.545 million shares repurchased for 75.3 million HKD as of June 30, 2025 [1] Group 2: Shareholding Changes - Allianz SE increased its stake in He Yu-B from 4.81% to 5.10% as of August 15 [1] Group 3: Financial Performance - He Yu-B reported a revenue of 657 million RMB for the first half of the year, representing a year-on-year growth of 20% [1] - The net profit for the same period was 328 million RMB, showing a significant increase of 59% year-on-year [1] - The company holds a cash reserve of 2.3 billion RMB, providing a solid foundation for future research and operations [1] Group 4: Product Development - The growth is primarily attributed to the core product, ABKS021 (Pimitespib), in collaboration with Merck, which exercised its global commercialization option in the first half of 2025, paying an option fee of 85 million USD [1] - The company is expected to achieve sustainable mid-term performance as it progresses towards the global approval and commercialization of Pimitespib, along with milestone payments and revenue sharing from sales [1]
港股异动 | 和誉-B(02256)涨超6%再创新高 公司连续回购并获外资股东增持 稳步推进匹米替尼注册上市